学术周报 · IF≥10
胃肠外科领域文献阅读汇编
2026年第41周 (2026-10-08) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Cancer cell | 2 | IF 56.1 |
| JAMA surgery | 2 | IF 15.6 |
| Endoscopy | 2 | IF 11.8 |
| Cell death and differentiation | 2 | IF 13.6 |
| Trends in cancer | 1 | IF 21.6 |
| Journal of obesity & metabolic syndrome | 1 | IF 12.7 |
| Gut | 1 | IF 24.6 |
| Molecular biomedicine | 1 | IF 13.0 |
| Cell metabolism | 1 | IF 37.0 |
| Science advances | 1 | IF 13.9 |
1胃癌/胃切除 (7篇)
临床研究 (3篇)
In the era of modern systemic chemotherapy, the optimal treatment strategy for gastric cancer with positive peritoneal lavage cytology (CY1) and/or localized peritoneal metastasis (P1a) remains controversial. To explore the optimal treatment strategy for patients with gastric cancer with CY1 and/or P1a by comparing the outcomes of various therapeutic strategies. This cohort study was a retrospective multicenter study set in 48 institutions of the Stomach Cancer Study Group in the Japan Clinical Oncology Group. Participants were patients with gastric cancer with CY1 and/or P1a, but no other distant metastases, who were treated in 2016 to 2022. Data were analyzed from July 2025 to May 2026. Patients were stratified according to initial treatment: upfront gastrectomy (n = 838 [71%]) or upfront chemotherapy (n = 343 [29%]). The upfront chemotherapy group was further subdivided into chemotherapy alone (n = 205), gastrectomy after conversion to P0CY0 (n = 92), and nonconversion gastrectomy (n = 46) according to preoperative chemotherapy efficacy. The primary outcome was overall survival (OS), and secondary outcomes included progression-free survival. Among 1181 patients, the median (IQR) age was 72 (65-78) years; 725 patients (61%) were male and 456 (39%) were female. The overall 5-year OS rate was 25.0% (95% CI, 22.3%-28.0%), with a median survival time of 24.3 months. Upfront gastrectomy showed a significantly longer OS than upfront chemotherapy (5-year OS: 27.6% vs 19.0%; hazard ratio, 0.80; 95% CI, 0.69-0.93; P = .004). Among the multimodal treatment strategies, upfront chemotherapy followed by gastrectomy showed a significantly higher 5-year OS rate than upfront gastrectomy with postoperative chemotherapy (39.9%; 95% CI, 31.7%-50.2%, vs 31.4%; 95% CI, 27.6%-35.8%; P = .01). Gastrectomy alone and chemotherapy alone showed poor prognoses (10.3% and 3.2%, respectively). Notably, survival after gastrectomy following conversion to P0CY0 was the most favorable (5-year OS: 50.5%), whereas that without P0CY0 was modest (5-year OS: 17.2%). This study found that for gastric cancer with CY1 and/or P1a, upfront chemotherapy followed by gastrectomy resulted in a slightly higher 5-year OS rate than upfront gastrectomy followed by postoperative chemotherapy. Because gastrectomy after conversion to P0CY0 was associated with the most favorable survival, the development of more effective preoperative chemotherapy is warranted.
中文摘要:在现代全身化疗时代,对于腹腔灌洗细胞学阳性(CY1)和/或局限性腹膜转移(P1a)的胃癌,最佳治疗策略仍存在争议。本研究通过比较各种治疗策略的结局,探讨CY1和/或P1a胃癌患者的最佳治疗策略。这项队列研究是一项回顾性多中心研究,开展于日本临床肿瘤学组胃癌研究组的48家机构。研究对象为2016年至2022年接受治疗的CY1和/或P1a、且无其他远处转移的胃癌患者。数据分析时间为2025年7月至2026年5月。患者按初始治疗分层:先行胃切除术(n=838,占71%)或先行化疗(n=343,占29%)。根据术前化疗疗效,先行化疗组进一步分为单纯化疗(n=205)、转化为P0CY0后行胃切除术(n=92)以及未转化即行胃切除术(n=46)。主要结局为总生存期(OS),次要结局包括无进展生存期。在1181例患者中,中位年龄(IQR)为72(65-78)岁;男性725例(61%),女性456例(39%)。总体5年OS率为25.0%(95%CI,22.3%-28.0%),中位生存时间为24.3个月。先行胃切除术的OS显著长于先行化疗(5年OS:27.6% vs 19.0%;风险比0.80;95%CI,0.69-0.93;P=.004)。在多模式治疗策略中,先行化疗后行胃切除术的5年OS率显著高于先行胃切除术后行术后化疗(39.9%;95%CI,31.7%-50.2% vs 31.4%;95%CI,27.6%-35.8%;P=.01)。单纯胃切除术和单纯化疗的预后较差(分别为10.3%和3.2%)。值得注意的是,转化为P0CY0后行胃切除术的生存最为理想(5年OS:50.5%),而未达到P0CY0者生存一般(5年OS:17.2%)。本研究发现,对于CY1和/或P1a胃癌,先行化疗后行胃切除术的5年OS率略高于先行胃切除术后行术后化疗。由于转化为P0CY0后行胃切除术与最理想的生存相关,因此有必要开发更有效的术前化疗。
The benefit of additional gastrectomy after eCuraC-2 non-curative endoscopic resection for early gastric cancer in older patients is uncertain because of competing mortality. This nationwide retrospective cohort included 1,038 patients aged ≥75 years with eCuraC-2 resection at 22 Korean hospitals (352 additional gastrectomy; 686 surveillance). The primary outcome was overall survival (OS). Secondary outcomes were gastric cancer (GC)-specific mortality and any recurrence. Multivariable Cox and competing-risk analyses were performed. Inverse probability of treatment weighting (IPTW) was used for sensitivity analysis. At 5 years, OS was 76.5% with surveillance versus 83.0% after additional gastrectomy (hazard ratio [HR] 1.37, 95% confidence interval [CI] 1.08-1.74; P=0.01). However, surveillance patients were older (≥80 years: 43.3% vs 24.1%) and more frequently had ECOG-PS 2-4 (11.7% vs. 6.8%), whereas gastrectomy patients had higher-risk pathology, including lymphovascular invasion (60.8% vs 37.0%). Although recurrence was more frequent with surveillance (9.9% vs. 1.8%; adjusted SHR 5.71, 95% CI 2.57-12.69), GC-specific death was rare (17 events; 1.3% vs. 1.1%). The unadjusted SHR for surveillance versus gastrectomy was imprecise (1.62, 95% CI 0.53-4.96; P=0.40), whereas the IPTW-weighted sensitivity estimate was larger (SHR 3.34, 95% CI 1.28-8.72; P=0.014). The derived all-cause/GC-specific mortality-rate ratios were 22.2 with surveillance and 27.3 after gastrectomy. In elderly patients with non-curative ESD, prognosis is driven more by competing non-GC mortality than by GC-related death. Additional gastrectomy may improve cancer-specific outcomes in selected patients, but its OS benefit appears limited. Management should therefore be individualized rather than based on curability criteria alone, balancing pathological risk against operative risk, postoperative functional consequences, physiological reserve, and patient preferences.
中文摘要:对于早期胃癌老年患者,eCuraC-2非治愈性内镜切除后追加胃切除术的获益因竞争性死亡风险而不确定。这项全国性回顾性队列纳入22家韩国医院中1,038例接受eCuraC-2切除且年龄≥75岁的患者(352例追加胃切除术;686例监测)。主要结局为总生存期(OS)。次要结局为胃癌(GC)特异性死亡和任何复发。采用多变量Cox分析和竞争风险分析。使用逆概率治疗加权(IPTW)进行敏感性分析。5年时,监测组OS为76.5%,追加胃切除术后为83.0%(风险比[HR] 1.37,95%置信区间[CI] 1.08-1.74;P=0.01)。然而,监测组患者年龄更大(≥80岁:43.3% vs 24.1%),且ECOG-PS 2-4更常见(11.7% vs 6.8%),而胃切除组具有更高风险病理,包括淋巴血管侵犯(60.8% vs 37.0%)。尽管监测组复发更频繁(9.9% vs 1.8%;校正SHR 5.71,95% CI 2.57-12.69),但GC特异性死亡罕见(17例事件;1.3% vs 1.1%)。监测组相较胃切除组的未校正SHR不精确(1.62,95% CI 0.53-4.96;P=0.40),而IPTW加权敏感性估计更大(SHR 3.34,95% CI 1.28-8.72;P=0.014)。推导的全因/GC特异性死亡率比值在监测组为22.2,胃切除术后为27.3。在非治愈性ESD的老年患者中,预后更多由竞争性非GC死亡而非GC相关死亡驱动。追加胃切除术可能在部分患者中改善癌症特异性结局,但其OS获益似乎有限。因此,治疗应个体化,而非仅基于可治愈性标准,需权衡病理风险与手术风险、术后功能后果、生理储备和患者偏好。
Chromatin remodeling is prominent in cancers, yet it remains obscure how chromatin dynamics underlies stepwise tumorigenesis and informs anti-cancer therapeutics. By decoding a large-scale chromatin accessibility atlas of 650 multistage samples from 439 patients, we delineate epigenetic switches spanning multistep gastric tumorigenesis. A cancer-resembling epigenetic priming state in intestinal metaplasia licenses subsequent tumor initiation. In advanced malignancies, inter-tumoral diversity stratifies three epigenomic subtypes. The proliferative and mesenchymal-inflammatory subtypes are sensitive to neoadjuvant immunotherapy, while the pseudo-gastric subtype is intrinsically drug resistant. Mechanistically, the refractory subtype is featured by a unique gastric lineage-mimicking phenotype, governed in part by FOSL2 to up-regulate H+/K+ ATPase transporters and sculpt an acidic milieu suppressing CD8+ T cells. Inhibition of this phenotype by either FOSL2 depletion or vonoprazan, a clinically available acid blocker, sensitizes immunotherapy. Collectively, these findings highlight that chromatin accessibility dynamics facilitates sequential tumorigenesis from gastric pre-cancer and defines subtypes exploitable to guide immunotherapy and overcome drug resistance.
中文摘要:染色质重塑在癌症中十分突出,然而染色质动态如何支撑逐步肿瘤发生并指导抗癌治疗仍不清楚。通过解码来自439例患者的650份多阶段样本的大规模染色质可及性图谱,我们描绘了贯穿多步骤胃肿瘤发生的表观遗传转换。肠化生中一种类似癌症的表观遗传预致敏状态允许后续肿瘤起始。在晚期恶性肿瘤中,肿瘤间多样性将其分为三种表观基因组亚型。增殖型和间充质-炎症型对新辅助免疫治疗敏感,而假胃型则内在耐药。机制上,难治亚型以独特的胃谱系模拟表型为特征,部分由FOSL2调控,上调H+/K+ ATP酶转运体并塑造抑制CD8+ T细胞的酸性微环境。通过FOSL2缺失或临床可用的酸阻断剂伏诺拉生抑制该表型,可使免疫治疗敏感化。总体而言,这些发现强调染色质可及性动态促进从胃癌前病变开始的序贯肿瘤发生,并定义了可用于指导免疫治疗和克服耐药性的亚型。
基础研究 (4篇)
Chromatin dynamics shape gastric cancer at every stage. In this issue of Cancer Cell, Wang et al. uncover a premalignant chromatin state primed for oncogenic activation alongside a pseudo-gastric subtype that hijacks acid secretion to evade antitumor immunity, revealing gastric proton pumps as a potential therapeutic target.
中文摘要:染色质动态塑造胃癌的每一个阶段。在本期《Cancer Cell》中,Wang等人揭示了一种为致癌激活做好准备的癌前染色质状态,同时发现一种伪胃亚型通过劫持酸分泌来逃避抗肿瘤免疫,提示胃质子泵可作为潜在治疗靶点。
Selecting effective chemotherapy after immunotherapy remains a major clinical challenge in advanced gastric cancer because patient responses are highly heterogeneous. A major obstacle is the lack of personalized preclinical models that faithfully recapitulate the immune-activated tumor microenvironment (TME) following immunotherapy and enable evaluation of subsequent chemotherapy responses while preserving immune-tumor interactions. Here, we developed an immune-activated co-culture model comprising patient-derived gastric cancer organoids and autologous peripheral blood mononuclear cells (PBMCs). Immune activation was achieved using anti-PD-1-loaded gold nanocages (aPD-1@Au NCs), which integrate near-infrared-triggered photothermal tumor ablation with sustained anti-PD-1-mediated immune modulation. The resulting model recapitulates key features of the post-immunotherapy TME, including enhanced immune-cell infiltration, increased tumor-cell apoptosis, and CD8+ T-cell activation. We then applied this model to evaluate five clinically relevant chemotherapeutic agents, including oxaliplatin, irinotecan, fluorouracil, doxorubicin, and docetaxel, for personalized chemotherapy screening after immunotherapy. Compared with monoculture organoids or non-activated co-cultures, the immune-activated model revealed drug-specific differences in tumor-killing efficacy, immune-mediated chemosensitization, and PBMC toxicity. Among the tested agents, oxaliplatin showed the strongest immune-mediated chemosensitization, whereas docetaxel achieved favorable tumor cell killing with relatively low immunotoxicity. These findings demonstrate that chemotherapy responses after immune activation are highly drug-specific, underscoring the importance of personalized chemotherapy selection following immunotherapy. As a proof-of-concept study, this work establishes an immune-activated patient-derived gastric cancer organoid-PBMC co-culture model that partially recapitulates the post-immunotherapy TME. This model provides a promising framework for developing personalized chemotherapy screening strategies after immunotherapy. STATEMENT OF SIGNIFICANCE: Selecting effective chemotherapy after immunotherapy remains a major challenge in advanced gastric cancer because of substantial interpatient heterogeneity. Progress in personalized treatment is limited by the lack of preclinical models that faithfully recapitulate the post-immunotherapy tumor microenvironment (TME). Here, we developed an immune-activated co-culture model integrating patient-derived gastric cancer organoids with autologous peripheral blood mononuclear cells (PBMCs). Immune activation was achieved using anti-PD-1-loaded gold nanocages (aPD-1@Au NCs), which combine near-infrared-triggered photothermal tumor ablation with sustained aPD-1-mediated immune modulation. This platform preserves patient-specific tumor characteristics while capturing key immune-tumor interactions following immunotherapy. Using this model, we evaluated five clinically relevant chemotherapeutic agents and identified distinct drug-specific differences in tumor-killing efficacy, immune-mediated chemosensitization, and immunotoxicity. As a proof-of-concept study, this work establishes a promising framework for personalized chemotherapy screening after immunotherapy and supports the development of precision treatment strategies for gastric cancer.
中文摘要:在晚期胃癌中,免疫治疗后选择有效的化疗仍是一项重大临床挑战,因为患者反应高度异质。一个主要障碍是缺乏能够忠实再现免疫治疗后免疫激活肿瘤微环境(TME),并在保留免疫-肿瘤相互作用的同时评估后续化疗反应的个体化临床前模型。在此,我们开发了一种免疫激活共培养模型,由患者来源的胃癌类器官和自体外周血单个核细胞(PBMC)组成。免疫激活通过载有抗PD-1的金纳米笼(aPD-1@Au NCs)实现,该纳米笼将近红外触发的光热肿瘤消融与持续的抗PD-1介导免疫调节相结合。所得模型再现了免疫治疗后TME的关键特征,包括免疫细胞浸润增强、肿瘤细胞凋亡增加和CD8+ T细胞激活。随后,我们应用该模型评估五种临床相关化疗药物,包括奥沙利铂、伊立替康、氟尿嘧啶、多柔比星和多西他赛,用于免疫治疗后的个体化化疗筛选。与单培养类器官或未激活共培养相比,免疫激活模型揭示了肿瘤杀伤效力、免疫介导的化疗增敏和PBMC毒性方面的药物特异性差异。在测试药物中,奥沙利铂显示出最强的免疫介导化疗增敏,而多西他赛在相对较低的免疫毒性下实现了良好的肿瘤细胞杀伤。这些发现表明,免疫激活后的化疗反应具有高度药物特异性,凸显了免疫治疗后个体化化疗选择的重要性。作为一项概念验证研究,本工作建立了一种免疫激活的患者来源胃癌类器官-PBMC共培养模型,该模型部分再现了免疫治疗后TME。该模型为开发免疫治疗后个体化化疗筛选策略提供了一个有前景的框架。意义声明:由于患者间存在显著异质性,免疫治疗后选择有效化疗仍是晚期胃癌的一大挑战。个性化治疗的进展受限于缺乏能够忠实再现免疫治疗后肿瘤微环境(TME)的临床前模型。在此,我们开发了一种免疫激活共培养模型,将患者来源的胃癌类器官与自体外周血单个核细胞(PBMC)整合。免疫激活通过载有抗PD-1的金纳米笼(aPD-1@Au NCs)实现,该纳米笼将近红外触发的光热肿瘤消融与持续的抗PD-1介导免疫调节相结合。该平台在保留患者特异性肿瘤特征的同时,捕捉免疫治疗后的关键免疫-肿瘤相互作用。利用该模型,我们评估了五种临床相关化疗药物,并识别出肿瘤杀伤效力、免疫介导化疗增敏和免疫毒性方面明显的药物特异性差异。作为一项概念验证研究,本工作为免疫治疗后个体化化疗筛选建立了一个有前景的框架,并支持胃癌精准治疗策略的开发。
The human gastric mucosa contends with insults throughout the course of its normal functions. Superficial injuries are rapidly resolved by the normal cellular lineages within the glandular epithelium. Deeper injuries often cause loss of acid-secreting cells, necessitating extensively coordinated repair mechanisms that significantly alter the cellular content of the gastric glands, culminating in pyloric metaplasia. Pyloric metaplasia is defined by the hyperplastic expansion of foveolar and mucous neck cell lineages as well as spasmolytic polypeptide-expressing metaplasia (SPEM) cells transdifferentiated from zymogenic chief cells. SPEM cells resemble mucus-secreting deep antral gland cells and possess proliferative qualities meant to aid in wound healing. Chief cell transdifferentiation into SPEM cells is regulated by an orderly process in which differentiated zymogenic cells reenter the cell cycle after downregulating mature transcriptional programs. The resolution of injury is followed by the restitution of normal cell lineages. However, metaplasia can persist when there is continuing inflammation and/or severe chronic injury. The aberrant persistence of proliferative SPEM cells can drive glandular intestinalization. The resulting intestinal metaplasia glands, particularly those with mixed gastric and intestinal lineages, are at increased risk for progression to dysplasia and ultimately gastric cancer. Understanding the dynamics of metaplastic cell lineage progression and uncovering lineage transition markers is critical to identifying targets suitable for therapeutic intervention. Here, we discuss the current knowledge, controversies, and remaining questions pertaining to the establishment and progression of metaplasia in response to deep gastric mucosal injury.
中文摘要:人胃黏膜在其正常功能过程中不断遭遇损伤。浅表损伤可由腺上皮内的正常细胞谱系迅速修复。较深的损伤常导致泌酸细胞丢失,需要广泛协调的修复机制,这些机制会显著改变胃腺的细胞组成,最终导致幽门腺化生。幽门腺化生的定义是胃小凹细胞和黏液颈细胞谱系的增生性扩张,以及由酶原性主细胞转分化而来的表达解痉多肽的化生(SPEM)细胞。SPEM细胞类似于分泌黏液的深部胃窦腺细胞,并具有旨在促进伤口愈合的增殖特性。主细胞向SPEM细胞的转分化受有序过程调控,其中分化成熟的酶原性细胞在下调成熟转录程序后重新进入细胞周期。损伤消退后,正常细胞谱系得以恢复。然而,当存在持续炎症和/或严重慢性损伤时,化生可持续存在。增殖性SPEM细胞的异常持续存在可驱动腺体肠化。由此形成的肠化生腺体,尤其是同时具有胃和肠谱系的腺体,进展为异型增生并最终发展为胃癌的风险增加。理解化生细胞谱系进展的动态并发现谱系转变标志物,对于确定适合治疗干预的靶点至关重要。在此,我们讨论关于深部胃黏膜损伤后化生建立与进展的当前知识、争议和遗留问题。
BTAF1, an ATP-dependent remodeler of the TBP-DNA complex, is frequently mutated in gastric cancer. However, its role in DNA repair and therapeutic relevance remains largely undefined. Here, we show that BTAF1 knockout leads to accumulation of double-strand breaks (DSBs) by impairing DNA end-resection process of homologous recombination (HR) repair, thereby sensitizing cells to genotoxic agents both in vitro and in vivo. Mechanistically, BTAF1 prevents ubiquitin-mediated degradation of MRE11, maintaining its protein stability, promoting DNA end resection and HR, and consequently enhancing cellular resistance to DNA-damaging stress. Notably, the interaction between BTAF1 and MRE11 is dynamically regulated by PARP1-mediated PARylation of BTAF1 during the DNA damage response. Loss of BTAF1 also increases chemosensitivity in gastric cancer xenograft and organoid models. Clinically, high BTAF1 expression correlates with poor prognosis in gastric cancer patients receiving neoadjuvant chemotherapy. Collectively, our findings identify BTAF1 as a critical regulator of HR repair through stabilization of MRE11 and propose BTAF1 as a potential biomarker for predicting response to genotoxic chemotherapy. BTAF1 is frequently mutated in gastric cancer, yet its role in DNA repair remains unclear. BTAF1 promotes homologous recombination and chemoresistance in gastric cancer by stabilizing MRE11. BTAF1 loss impairs DNA end resection, sensitizing cells to genotoxic agents. The BTAF1-MRE11 interaction is regulated by PARP1 mediated PARylation.
中文摘要:BTAF1 是 TBP-DNA 复合物的 ATP 依赖性重塑因子,在胃癌中频繁发生突变。然而,其在 DNA 修复中的作用及治疗相关性在很大程度上仍未明确。在此,我们发现 BTAF1 敲除会通过损害同源重组(HR)修复中的 DNA 末端切除过程,导致双链断裂(DSB)积累,从而使细胞在体外和体内均对遗传毒性药物敏感。机制上,BTAF1 可阻止 MRE11 经泛素介导的降解,维持其蛋白稳定性,促进 DNA 末端切除和 HR,进而增强细胞对 DNA 损伤应激的抵抗。值得注意的是,在 DNA 损伤应答过程中,BTAF1 与 MRE11 之间的相互作用受 PARP1 介导的 BTAF1 PAR化动态调控。BTAF1 缺失还可提高胃癌异种移植瘤和类器官模型的化疗敏感性。临床上,高 BTAF1 表达与接受新辅助化疗的胃癌患者预后不良相关。总之,我们的发现表明 BTAF1 通过稳定 MRE11 成为 HR 修复的关键调控因子,并提出 BTAF1 可作为预测遗传毒性化疗反应的潜在生物标志物。BTAF1 在胃癌中频繁突变,但其在 DNA 修复中的作用仍不明确。BTAF1 通过稳定 MRE11 促进胃癌中的同源重组和化疗耐药。BTAF1 缺失会损害 DNA 末端切除,使细胞对遗传毒性药物敏感。BTAF1-MRE11 相互作用受 PARP1 介导的 PAR化调控。
2减重/代谢手术 (4篇)
临床研究 (3篇)
Obesity remains a growing global health crisis, affecting nearly one billion adults worldwide and substantially increasing the risk of cardiometabolic disease, malignancy, and premature mortality. Metabolic and bariatric surgery (MBS) has evolved into an effective and durable treatment for severe obesity, providing sustained weight loss and significant remission of obesity-related comorbidities (i.e., type 2 diabetes mellitus and cardiovascular disease). Despite dramatic improvements in safety, efficacy, and long-term outcomes over time, MBS remains markedly underutilized, reaching fewer than 1% of eligible patients. Persistent barriers include limited patient and provider awareness, misconceptions regarding surgical risk, and significant disparities in access to care. Concurrently, the rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has transformed the medical management of obesity, offering effective pharmacologic weight loss but raising questions regarding their impact on MBS utilization, durability, and cost-effectiveness. Emerging evidence demonstrates that while MBS produces greater and more durable weight loss than GLP-1 RAs alone, these therapies need not be competitive. Rather, GLP-1 RAs may serve as 'neoadjuvant' treatment to optimize surgical candidacy or as adjunctive treatment for inadequate weight loss or postoperative weight regain. This review synthesizes contemporary data on MBS procedures, outcomes, disparities in access, and evolving perceptions of obesity treatment in the GLP-1 RA era. We propose a chronic weight management model that integrates pharmacotherapy, surgery, and multidisciplinary care along a continuous treatment spectrum. Positioning MBS and GLP-1 RAs as complementary modalities within individualized care pathways may improve long-term outcomes, expand access, and better address the complex, chronic nature of obesity.
中文摘要:肥胖仍是一场不断加剧的全球健康危机,影响全球近十亿成年人,并显著增加心脏代谢疾病、恶性肿瘤和过早死亡的风险。代谢与减重手术(MBS)已发展为治疗重度肥胖的有效且持久的方法,可实现持续减重,并显著缓解肥胖相关合并症(如2型糖尿病和心血管疾病)。尽管多年来在安全性、疗效和长期结局方面已有显著改善,MBS仍明显未被充分利用,仅覆盖不到1%的符合条件的患者。持续存在的障碍包括患者和提供者认知有限、对手术风险的误解以及获得医疗照护方面的显著差异。与此同时,胰高血糖素样肽-1受体激动剂(GLP-1 RAs)的快速应用改变了肥胖的药物治疗,提供了有效的药物减重,但也引发了关于其对MBS使用、持久性和成本效果影响的疑问。新出现的证据表明,虽然MBS比单用GLP-1 RAs能产生更大且更持久的减重效果,但这些疗法不必相互竞争。相反,GLP-1 RAs可作为「新辅助」治疗以优化手术候选资格,或作为辅助治疗用于减重不足或术后体重反弹。本综述综合了关于MBS术式、结局、获得治疗方面的差异以及GLP-1 RA时代肥胖治疗观念演变的最新数据。我们提出一种慢性体重管理模型,将药物治疗、手术和多学科照护整合为一个连续的治疗谱系。将MBS和GLP-1 RAs定位为个体化照护路径中的互补方式,可能改善长期结局、扩大可及性,并更好地应对肥胖复杂、慢性的本质。
Vitamin B12 deficiency is common in older adults, atrophic gastritis, and after bariatric surgery, and can cause irreversible neurological injury. Oral, sublingual, and intramuscular routes all correct serum concentrations, yet whether any route is superior for clinically meaningful outcomes is unclear, and international guidelines diverge. This consensus was convened to define where evidence is adequate, where it is lacking, and the priority research questions. This was a modified Delphi consensus study. The RAND/UCLA Appropriateness Method was applied through a two-stage process of 2 electronic rounds and an in-person meeting in São Paulo, Brazil. Panellists were recruited between 1 July 2025 and 15 July 2025. Thirty statements were voted on, presented as 31 graded items, using a binary (agree or disagree) format with a priori percentage-agreement grades (A+, 100%; A, 90%-99.9%; B, 80%-89.9%; C, 70%-79.9%; and D, 66%-69.9%). Draft statements, informed by a systematic review, were rated anonymously by a Brazilian multidisciplinary panel of 20 experts across haematology, gastroenterology, endocrinology, bariatric surgery, and geriatric medicine/neurology. Of 20 experts invited, all 20 agreed to participate and completed the electronic rounds (100%); 16 (80%) attended the in-person meeting. Patient representatives (n = 2) participated as non-voting observers. Grade A (at least 90% agreement) was the stopping rule. This consensus was not registered. In total, 30 statements across 6 modules were agreed, comprising 31 separately graded items as statement 1 was presented in two parts (1a and 1b); 22 of 31 items (71%) reached grade A+ (100% agreement) and 9 of 31 (29%) reached grade A (90%-99.9%). All routes were judged capable of normalising serum vitamin B12, but none showed proven superiority for symptom resolution, neurological recovery, functional status, or quality of life. Evidence gaps were greatest after bariatric surgery, in older adults with cognitive impairment or frailty, and in pernicious anaemia. Dosing, monitoring, and response definitions varied substantially. Vitamin B12 replacement across all routes remains guided primarily by biochemical rather than clinical evidence. Treatment should be individualised by aetiology, patient preference, feasibility, and access, with functional biomarkers and clinical assessment complementing serum levels. Adequately powered, long-term comparative trials using standardised, patient-centred outcomes are the priority. This work was funded by Myralis Indústria Farmacêutica Ltda, São Paulo, Brazil.
中文摘要:维生素B12缺乏在老年人、萎缩性胃炎及减重手术后常见,并可导致不可逆的神经损伤。口服、舌下及肌内注射途径均可纠正血清浓度,但是否任一途径在具有临床意义结局方面更优尚不清楚,且国际指南存在分歧。本次共识旨在明确证据充分之处、证据不足之处以及优先研究问题。本研究为改良德尔菲共识研究。采用RAND/UCLA适宜性方法,通过两阶段流程进行,包括2轮电子投票和在巴西圣保罗举行的面对面会议。专家组成员于2025年7月1日至7月15日期间招募。对30条陈述进行投票,以31个分级条目呈现,采用二分类(同意或不同意)形式,并预先设定百分比一致度分级(A+,100%;A,90%-99.9%;B,80%-89.9%;C,70%-79.9%;D,66%-69.9%)。在系统评价基础上形成的陈述草案,由巴西多学科专家组匿名评分,专家组由20名专家组成,涵盖血液学、胃肠病学、内分泌学、减重外科以及老年医学/神经病学。受邀的20名专家均同意参与并完成电子轮次(100%);16名(80%)参加了面对面会议。患者代表(n=2)作为无投票权观察员参与。以A级(一致度至少90%)为停止规则。本共识未注册。最终就6个模块的30条陈述达成一致,由于陈述1分为两部分(1a和1b)呈现,共包含31个单独分级条目;31个条目中有22个(71%)达到A+级(100%一致),9个(29%)达到A级(90%-99.9%)。所有途径均被认为能够使血清维生素B12正常化,但尚无任何途径在症状缓解、神经功能恢复、功能状态或生活质量方面显示出确切优势。证据缺口在减重手术后、伴有认知障碍或衰弱的老年人以及恶性贫血中最大。给药、监测和应答定义差异很大。所有途径的维生素B12替代治疗仍主要依据生化证据而非临床证据。治疗应根据病因、患者偏好、可行性和可及性进行个体化,并以功能性生物标志物和临床评估补充血清水平。采用标准化、以患者为中心的结局指标,开展有足够把握度的长期比较试验是优先事项。本研究由巴西圣保罗的Myralis Indústria Farmacêutica Ltda资助。
Endoscopic sleeve gastroplasty (ESG) facilitates 13.6%-16.2% total body weight loss (TBWL) at 12 months, but falls short of that seen with surgical vertical sleeve gastrectomy, in part owing to the retention of the gastric fundus. In adults with obesity, gastric fundal mucosal ablation (GFMA) reduces fasting plasma ghrelin (FPG), hunger, cravings, and accommodation. Combined GFMA-ESG could improve TBWL. This study aimed to evaluate the effectiveness and safety of sequential GFMA followed by ESG in adults with obesity, building on previously published 6-month results of GFMA alone. This was a prospective, first-in-human, two-phase clinical trial. Ten participants underwent GFMA, followed by ESG at month 6, and were followed for 12 months post-ESG (18 months total). GFMA was performed using hybrid argon plasma coagulation to lift and ablate the entire gastric fundal mucosa. ESG was performed using standard full-thickness endoscopic suturing of the gastric body. The primary end point was TBWL; secondary end points were safety and changes in FPG, maximum tolerated volume (MTV), and validated appetite questionnaires. Mean TBWL was 22.5% (SD 8.3%) at month 18. Hunger-related behaviors and eating self-efficacy showed sustained improvements. FPG was decreased at month 6 and returned toward baseline by month 18, while MTV remained suppressed. No serious adverse events occurred. Sequential GFMA-ESG is safe and induces substantial weight loss, reduced MTV of ingested nutrients, and improved behavioral measures. This combination approach builds on prior traditional ESG and GFMA-only results and may represent a promising advancement of endoscopic therapeutic options for weight loss.
中文摘要:内镜下袖状胃成形术(ESG)可在12个月时带来13.6%–16.2%的总体重下降(TBWL),但低于外科垂直袖状胃切除术的效果,部分原因在于胃底得以保留。在成人肥胖症患者中,胃底黏膜消融(GFMA)可降低空腹血浆胃饥饿素(FPG)、饥饿感、渴求感和胃容受性。GFMA联合ESG可能改善TBWL。本研究旨在评估在成人肥胖症患者中序贯进行GFMA后行ESG的有效性和安全性,并建立在既往已发表的单纯GFMA 6个月结果基础上。这是一项前瞻性、首次人体、两阶段临床试验。10名受试者接受GFMA,随后在第6个月接受ESG,并在ESG后随访12个月(总计18个月)。GFMA采用混合氩离子凝固术对全部胃底黏膜进行抬举和消融。ESG采用标准全层内镜下胃体缝合术完成。主要终点为TBWL;次要终点为安全性以及FPG、最大耐受量(MTV)和经验证食欲问卷的变化。第18个月时平均TBWL为22.5%(标准差8.3%)。饥饿相关行为和进食自我效能持续改善。FPG在第6个月下降,至第18个月回落至基线附近,而MTV仍持续受抑制。未发生严重不良事件。序贯GFMA-ESG安全,并可诱导显著体重下降、降低摄入营养素的最大耐受量,并改善行为学指标。这种联合方案建立在既往传统ESG和单纯GFMA结果之上,可能代表内镜减重治疗选择的有前景的进展。
基础研究 (1篇)
Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most prevalent chronic liver diseases worldwide, characterized primarily by excessive lipid droplet (LD) accumulation in hepatocytes. Bariatric surgery, particularly sleeve gastrectomy (SG), represents the most effective intervention for reversing MASLD, although the underlying mechanisms remain incompletely understood. This study aimed to investigate the mitochondrial and lipid droplets (LDs) related molecular mechanisms by which SG ameliorated MASLD. Using a high-fat diet (HFD)-induced mouse model of MASLD, combined with SG intervention, hepatocyte-specific genetic manipulation, multi-omics analysis, and mitochondrial ultrastructural examination, we observed that MASLD was associated with a marked upregulation of perilipin 5 (PLIN5) on the LD surface and mitochondrial fission factor (MFF) on the mitochondrial outer membrane. Ultrastructural and co-immunoprecipitation (Co-IP) analyses revealed that PLIN5 and MFF formed a complex that facilitated the recruitment of LDs to mitochondria and their penetration into the mitochondrial matrix. This process ultimately led to disrupted mitochondrial fatty acid β-oxidation and structural disorganization. SG significantly downregulated PLIN5 and MFF expression, reduced LD-induced mitochondrial damage, and enhanced mitochondrial resilience to high-fat stress. These changes might contribute to the restoration of mitochondria-LD structural and functional homeostasis, ultimately reversing MASLD. Our findings indicated that aberrant upregulation of MFF contributed to MASLD progression, and SG might alleviate the disease by suppressing the MFF-PLIN5 axis to normalize mitochondria-LD interactions. These results suggested that targeting the MFF-PLIN5 axis may offer a promising therapeutic strategy for non-surgical management of MASLD.
中文摘要:代谢功能障碍相关脂肪性肝病(MASLD)是全球最常见的慢性肝病之一,其主要特征是肝细胞内脂滴(LD)过度积聚。减重手术,尤其是袖状胃切除术(SG),是逆转MASLD最有效的干预措施,但其潜在机制仍未完全阐明。本研究旨在探讨SG改善MASLD的线粒体与脂滴(LDs)相关分子机制。我们采用高脂饮食(HFD)诱导的MASLD小鼠模型,并结合SG干预、肝细胞特异性基因操作、多组学分析以及线粒体超微结构检查,观察到MASLD与脂滴表面脂滴包被蛋白5(PLIN5)和线粒体外膜上的线粒体分裂因子(MFF)显著上调相关。超微结构和免疫共沉淀(Co-IP)分析显示,PLIN5与MFF形成复合物,促进脂滴募集至线粒体并使其穿入线粒体基质。该过程最终导致线粒体脂肪酸β氧化受损和结构紊乱。SG显著下调PLIN5和MFF表达,减轻脂滴诱导的线粒体损伤,并增强线粒体对高脂应激的耐受性。这些变化可能有助于恢复线粒体-脂滴结构与功能稳态,最终逆转MASLD。我们的发现表明,MFF异常上调促进MASLD进展,而SG可能通过抑制MFF-PLIN5轴以正常化线粒体-脂滴相互作用来缓解该病。这些结果提示,靶向MFF-PLIN5轴可能为MASLD的非手术治疗提供一种有前景的治疗策略。
3结直肠外科 (3篇)
临床研究 (2篇)
The emergence of tumor-agnostic therapies has fundamentally transformed precision oncology. Traditionally developed and approved for metastatic disease, nine therapies spanning immunotherapy, targeted agents, and antibody-drug conjugates now demonstrate a compelling rationale for earlier deployment in the neoadjuvant setting. This review examines the paradigm shift from last-resort to first-consideration approaches. Key advantages of neoadjuvant, biomarker-guided therapy include intervention prior to the development of therapeutic resistance, optimal immune system engagement, and opportunities for organ preservation. Single-agent programmed cell death protein-1 blockade has achieved a 100% complete response rate in mismatch repair-deficient rectal cancer with preserved organ function. Neurotrophic tyrosine receptor kinase (NTRK), rearranged during transfection (RET), and B-Raf proto-oncogene serine/threonine kinase (BRAF) inhibitors have demonstrated substantial responses that enable curative-intent surgery across malignancies. As precision oncology matures, the neoadjuvant tumor-agnostic approach exemplifies optimized therapeutic sequencing, potentially improving patient outcomes and quality of life.
中文摘要:肿瘤不可知疗法的出现从根本上改变了精准肿瘤学。传统上针对转移性疾病开发和批准的九种疗法,涵盖免疫治疗、靶向药物和抗体药物偶联物,如今显示出在更早的新辅助治疗阶段应用的令人信服的理由。本综述探讨了从最后手段到首先考虑的方法的范式转变。新辅助、生物标志物指导治疗的关键优势包括在治疗耐药发生前进行干预、最佳地调动免疫系统以及器官保留的机会。单药程序性细胞死亡蛋白-1阻断在错配修复缺陷直肠癌中达到100%完全缓解率,并保留了器官功能。神经营养酪氨酸受体激酶(NTRK)、转染重排(RET)和B-Raf原癌基因丝氨酸/苏氨酸激酶(BRAF)抑制剂已显示出实质性缓解,使多种恶性肿瘤能够进行以治愈为目的的手术。随着精准肿瘤学日益成熟,新辅助肿瘤不可知方法体现了优化的治疗排序,可能改善患者结局和生活质量。
Type 2 diabetes (T2D) is a heterogeneous disease, yet current classifications do not capture its clinico-biological complexity or support precision-based care. We developed an endotyping strategy based on routine blood immune cell counts across more than 1,500 individuals with newly diagnosed T2D from three European cohorts. Unsupervised clustering identified four reproducible immune endotypes: severe inflammatory diabetes (SIND), mild inflammatory diabetes (MIND), lymphocyte-rich diabetes (LYRD), and lymphocyte-deficient diabetes (LYDD). Endotypes were stable, robust to de novo clustering, and independent of age, sex, BMI, and HbA1c. SIND and LYDD were associated with increased cardiovascular, renal, and mortality risk across cohorts. Immune endotyping improved cardiovascular risk prediction beyond SCORE2-Diabetes. Multi-omic profiling revealed immunopathological states, with high-risk endotypes characterized by monocyte-driven inflammation and dysregulated lymphocyte programs. The inflammatory profile of SIND was attenuated by IL-1β antagonism and bariatric surgery. These findings establish immune endotyping as a scalable framework for immunometabolic risk stratification in T2D.
中文摘要:2型糖尿病(T2D)是一种异质性疾病,然而当前分类未能捕捉其临床-生物学复杂性,也无法支持精准医疗。我们基于三个欧洲队列中1500余名新诊断T2D患者的常规血液免疫细胞计数,开发了一种内型分型策略。无监督聚类识别出四种可重复的免疫内型:重度炎症型糖尿病(SIND)、轻度炎症型糖尿病(MIND)、淋巴细胞丰富型糖尿病(LYRD)和淋巴细胞缺陷型糖尿病(LYDD)。这些内型稳定,对从头聚类稳健,且独立于年龄、性别、BMI和HbA1c。在各队列中,SIND和LYDD与心血管、肾脏及死亡风险增加相关。免疫内型分型在SCORE2-Diabetes之外改善了心血管风险预测。多组学分析揭示了免疫病理状态,其中高风险内型以单核细胞驱动的炎症和淋巴细胞程序失调为特征。SIND的炎症特征可被IL-1β拮抗和减重手术减弱。这些发现确立了免疫内型分型作为T2D免疫代谢风险分层可扩展框架的地位。
基础研究 (1篇)
During tissue regeneration, cells are recruited from surrounding tissue to the defect site. However, when the defect site is large and morphologically complex, cell recruitment often fails to match healthy tissue morphology, resulting in a dysfunctional repair. The integration of bioscaffolds can help to direct the repair process. Here, we present a protocol that integrates electrospinning, weaving, thermal fixation and modified gas-foaming technologies to fabricate 3D hierarchically aligned nanofiber scaffolds. The scaffolds exhibit high porosity, controlled fiber alignment and diverse configurations (uniaxial, bidirectional, radial and gradient alignments), creating effective 'cell highways' for promoting collective cell migration. Applications include hemostatic materials, skin and bone regeneration, hernia repair and biomedical swabs. Both in vitro and in vivo, the highly porous and directionally arranged 3D nanofiber scaffolds markedly enhance cell migration, accelerating the reconstruction of defective tissues. This protocol resolves challenges in production scalability, facilitating the wider adoption of these scaffolds, with a procedure intended for users with expertise in biomaterials and regenerative medicine. The 3D nanofiber scaffolds require 1 d to synthesize and result in improved cell migration during in situ tissue regeneration.
中文摘要:在组织再生过程中,细胞会从周围组织被募集到缺损部位。然而,当缺损部位较大且形态复杂时,细胞募集往往难以与健康组织形态相匹配,从而导致功能不良的修复。生物支架的整合有助于引导修复过程。在此,我们提出一种方案,整合静电纺丝、编织、热固定和改良气体发泡技术,以制备三维分级排列的纳米纤维支架。这些支架具有高孔隙率、可控的纤维排列以及多种构型(单轴、双向、径向和梯度排列),可形成有效的「细胞高速公路」,促进细胞集体迁移。应用包括止血材料、皮肤与骨再生、疝修补以及生物医学拭子。无论在体外还是体内,高孔隙率且定向排列的三维纳米纤维支架均显著增强细胞迁移,加速缺损组织的重建。该方案解决了生产可扩展性方面的挑战,有助于促进这些支架的更广泛应用,其操作流程面向具备生物材料和再生医学专业知识的使用者。三维纳米纤维支架的合成需要1天,并可在原位组织再生过程中改善细胞迁移。
4直肠癌/TME (2篇)
临床研究 (2篇)
In the past 5 years, clinical trials on immune checkpoint inhibitors (ICIs) for the treatment of locally advanced rectal cancer (LARC) have flourished globally, and China has become one of the leading regions in this field. In response to the breakthrough progress and accumulation of evidence from key clinical trials, the Chinese Society of Colorectal Surgery has recognised the need for updated consensus guidance on the development of perioperative and organ-preserving treatment strategies for LARC. This expert consensus guidance provided unified standards for the indications, medication regimens, efficacy evaluations and follow-up of ICIs in this population, with a focus mainly on perioperative management and organ-sparing strategies. The diagnostic part of this consensus guidance is based on the internationally recognised definition of mismatch repair/microsatellite instability detection and emphasises the importance of multidisciplinary teams in treatment decision-making. In terms of treatment, based on the results of key trials that have changed clinical practice in the past 5 years, this expert consensus provides graded recommendations for the duration of preoperative immunotherapy and the necessity of postoperative adjuvant therapy, local resection and organ preservation strategies. Moreover, we refined the management process for the safety of perioperative immunotherapy. This document aims to provide a reference for surgeons; internal medicine, radiation therapy, pathology and imaging physicians; patients and nursing staff involved in the treatment of LARC, as well as health policy makers.
中文摘要:过去5年中,针对局部晚期直肠癌(LARC)治疗的免疫检查点抑制剂(ICIs)临床试验在全球蓬勃发展,中国已成为该领域的领先地区之一。面对关键临床试验取得的突破性进展和不断积累的证据,中国结直肠外科学会认识到,有必要更新关于LARC围手术期和器官保留治疗策略制定的共识指导。本专家共识指导为该人群ICIs的适应证、用药方案、疗效评估和随访提供了统一标准,重点聚焦于围手术期管理和器官保留策略。本共识指导的诊断部分基于国际公认的错配修复/微卫星不稳定性检测定义,并强调多学科团队在治疗决策中的重要性。在治疗方面,基于过去5年中改变临床实践的关键试验结果,本专家共识对术前免疫治疗的时长及术后辅助治疗的必要性、局部切除和器官保留策略提供了分级推荐。此外,我们完善了围手术期免疫治疗安全性的管理流程。本文档旨在为外科医生,参与LARC治疗的内科、放疗、病理和影像科医生,患者和护理人员,以及卫生政策制定者提供参考。
Adhesions commonly occur after abdominal and pelvic surgery, causing infertility, intestinal obstruction, and pelvic pain. Existing anti-adhesion materials are often difficult to use on uneven organ surfaces, highlighting the need for novel solutions; SI-449, a cross-linked, powder-formed chondroitin sulfate (CS), may address these limitations. To evaluate the anti-adhesion effect of the SI-449 adhesion barrier system (cs barrier) in patients undergoing open rectal resection for rectal cancer. This multicenter, prospective, randomized, open, and blinded-end point (PROBE) method pivotal clinical trial was conducted at 53 hospitals in Japan from September 2020 to June 2023. The study participants and efficacy assessors on the central review board were blinded. Patients aged 20 years or older with clinical stage I through IV rectal cancer who underwent open rectal resection and were scheduled for follow-up ileostomy closure were eligible for inclusion. Data were analyzed from July 2023 through September 2023. The control group received no additional procedure before abdominal closure, while the experimental group received 2 to 3 g of SI-449 applied to the abdominal or pelvic cavity immediately before closure. The primary end point was the incidence of adhesions under the incision. Secondary end points included adhesion number, severity, and extent; number and type of adhered organs; and number of adhesions per organ. Safety and operability were also evaluated. Among 155 screened patients, 131 met the inclusion criteria and were randomized. Of these, 128 underwent the intervention (safety analysis population; control group: n = 64; experimental group: n = 64), and 118 completed a second surgery (modified intention-to-treat population; control group: n = 60; experimental group: n = 58). Overall mean (SD) patient age was 68.2 (10.3) years, and 34 patients of 118 (29%) were female. Adhesion incidence was significantly lower in the experimental group (26 of 58 [45%]) compared to the control group (56 of 60 [93%]) (P < .001). The experimental group also showed significantly reduced adhesion severity and extent. No safety concerns were identified, and operability was good. In this randomized clinical trial, SI-449 in the powdered form reduced the incidence of adhesions, and the adhesion barrier system had good operability and no safety concerns. Thus, this system may provide a new anti-adhesion option for use in open surgery. jrct.mhlw.go.jp Identifier: jRCT1080225247.
中文摘要:腹部和盆腔手术后常发生粘连,导致不孕、肠梗阻和盆腔疼痛。现有防粘连材料通常难以用于不平整的器官表面,凸显了对新型解决方案的需求;SI-449是一种交联、粉末形式的硫酸软骨素(CS),可能解决这些局限。旨在评估SI-449防粘连屏障系统(CS屏障)在接受开放直肠切除术的直肠癌患者中的防粘连效果。这项多中心、前瞻性、随机、开放、盲法终点(PROBE)的关键性临床试验于2020年9月至2023年6月在日本53家医院开展。研究参与者和中央审查委员会中的疗效评估者设盲。年龄20岁及以上、临床I至IV期直肠癌、接受开放直肠切除术并计划进行回肠造口还纳术以随访的患者符合纳入条件。数据分析时间为2023年7月至2023年9月。对照组在关腹前未接受额外操作,而试验组在关腹前即刻将2至3 g SI-449应用于腹腔或盆腔。主要终点为切口下方粘连的发生率。次要终点包括粘连数量、严重程度和范围;粘连器官的数量和类型;以及每个器官的粘连数量。还评估了安全性和可操作性。在155例筛选患者中,131例符合纳入标准并被随机分组。其中128例接受了干预(安全性分析人群;对照组:n=64;试验组:n=64),118例完成了第二次手术(改良意向治疗人群;对照组:n=60;试验组:n=58)。总体患者平均(SD)年龄为68.2(10.3)岁,118例患者中34例(29%)为女性。试验组粘连发生率(58例中26例[45%])显著低于对照组(60例中56例[93%])(P<.001)。试验组还显示粘连严重程度和范围显著降低。未发现安全性问题,且可操作性良好。在这项随机临床试验中,粉末形式的SI-449降低了粘连发生率,该防粘连屏障系统具有良好的可操作性且无安全性问题。因此,该系统可能为开放手术提供一种新的防粘连选择。jrct.mhlw.go.jp标识符:jRCT1080225247。
5胃癌 (2篇)
基础研究 (2篇)
In situ cancer vaccines exhibit promising therapeutic potential; however, their efficacy is constrained by limited antigen release, suboptimal spatiotemporal immune coordination, and adaptive immune resistance. In this study, we identify zinc ions (Zn2+) as synergistic agents with chemotherapeutics in modulating PANoptosis and immune signaling pathways. Capitalizing on this concept, a chemo-metallic nanodriver was developed for effective in situ cancer vaccination. This system used zinc-aluminum layered double hydroxides as the structural base and efficiently loaded cisplatin (DDP) and indocyanine green via coordination-driven polymerization, forming a spatiotemporally controllable nanodriver, which facilitated the simultaneous release of drug and metal ions upon photoactivation. The released Zn2+ specifically disrupted zinc homeostasis in tumor cells, inducing mitochondrial dysfunction. This effect acted in concert with DDP-mediated DNA damage, not only effectively activating the cGAS-STING (cyclic GMP-AMP synthase-stimulator of interferon genes) pathway but also promoting the assembly and activation of AIM2-PANoptosome complex to execute PANoptosis. This STING-PANoptosis cascade led to a burst release of damage-associated molecular patterns, markedly enhanced dendritic cell maturation, and stimulated the secretion of pro-inflammatory cytokines. Furthermore, the nanodriver elicited a robust antitumor immune response and established durable immune memory in mouse models. These findings not only provide an optimized strategy for precise immunotherapy of gastric cancer but also increase the understanding of the applications of metal ion immunology and PANoptosis in disease intervention.
中文摘要:原位癌症疫苗展现出有前景的治疗潜力;然而,其疗效受限于抗原释放有限、时空免疫协调欠佳以及适应性免疫抵抗。在本研究中,我们发现锌离子(Zn2+)可与化疗药物协同调节PANoptosis和免疫信号通路。基于这一概念,开发了一种化疗-金属纳米驱动器用于有效的原位癌症疫苗接种。该系统以锌铝层状双氢氧化物为结构基础,通过配位驱动聚合高效负载顺铂(DDP)和吲哚菁绿,形成时空可控的纳米驱动器,其在光激活后促进药物和金属离子的同时释放。释放的Zn2+特异性破坏肿瘤细胞中的锌稳态,诱导线粒体功能障碍。该效应与DDP介导的DNA损伤协同作用,不仅有效激活cGAS-STING(环状GMP-AMP合成酶-干扰素基因刺激因子)通路,还促进AIM2-PANoptosome复合物的组装和激活以执行PANoptosis。这一STING-PANoptosis级联反应导致损伤相关分子模式爆发释放,显著增强树突状细胞成熟,并刺激促炎细胞因子分泌。此外,该纳米驱动器在小鼠模型中引发强效抗肿瘤免疫反应并建立持久免疫记忆。这些发现不仅为胃癌的精准免疫治疗提供了一种优化策略,也增进了对金属离子免疫学和PANoptosis在疾病干预中应用的理解。
Chemoradiotherapy resistance remains a major obstacle in gastric cancer treatment, primarily due to enhanced DNA repair mechanisms that allow tumor cells to overcome therapeutic damage. Here, we demonstrate that nuclear-localized Exocyst Complex Component 4 (EXOC4) promotes chemoradiotherapy resistance in gastric cancer by enhancing non-homologous end joining-mediated DNA repair. Specifically, p300-mediated acetylation of EXOC4 at lysine 433 induces its nuclear translocation. In the nucleus, EXOC4 facilitates the interaction between PRMT5 and KU70, inducing PRMT5-catalyzed methylation of KU70 at arginine 318. This modification increases the DNA-binding affinity of the KU complex, thereby accelerating double-strand break repair. A peptide targeting EXOC4 K433 inhibits acetylation-dependent nuclear import, reducing KU70 methylation and restoring chemoradiotherapy sensitivity in preclinical models. Collectively, our findings identify the p300-EXOC4-KU70 axis as a critical mediator of chemoradiotherapy resistance and a promising therapeutic target.
中文摘要:放化疗耐药仍是胃癌治疗中的主要障碍,主要原因在于DNA修复机制增强,使肿瘤细胞能够克服治疗损伤。在此,我们证明,核内定位的Exocyst复合体组分4(EXOC4)通过增强非同源末端连接介导的DNA修复,促进胃癌的放化疗耐药。具体而言,p300介导的EXOC4在赖氨酸433位点的乙酰化诱导其核转位。在细胞核中,EXOC4促进PRMT5与KU70之间的相互作用,诱导PRMT5催化KU70在精氨酸318位点的甲基化。该修饰增加了KU复合物的DNA结合亲和力,从而加速双链断裂修复。一种靶向EXOC4 K433的肽抑制乙酰化依赖的核输入,降低KU70甲基化,并在临床前模型中恢复放化疗敏感性。总之,我们的研究结果确立了p300-EXOC4-KU70轴是放化疗耐药的关键介质和有前景的治疗靶点。
6其他 (1篇)
临床研究 (1篇)
Excessive postoperative inflammation is associated with multisystem complications after surgery, culminating in morbidity, mortality and increased healthcare costs. Epigenetic modifications regulate gene transcription without altering DNA sequences and can augment powerful inflammatory responses. Translational studies have emerged, investigating how epigenetic mechanisms influence perioperative inflammation and complications. This scoping review consolidates studies in this expanding field and provides informed recommendations for future research. The protocol for this scoping review was created using best-practice guidelines and was prospectively registered and published. Searches were conducted using Medline and Embase and included studies published in English between 1946 and 2025. Two reviewers independently screened titles and abstracts, then full texts of studies before data extraction. Included studies investigated postoperative complications alongside epigenetic mechanisms and inflammation. Studies (n=15 451) were assessed for title and abstract screening, and 26 articles were included in the review. Included studies were published between 2016 and 2025. Cardiac surgery was investigated most often, followed by general and colorectal surgery. Several surgical specialities were not represented. Most studies investigated microRNA mechanisms, investigating either a small number of microRNAs (≤8) or using whole transcriptome approaches. DNA methylation and histone modifications were investigated less commonly. Complications were variably defined in the included studies, and most studies focused on a small number of complications. Inflammation was heterogeneously assessed, with most studies using C-reactive protein and interleukin-6 or both, whereas other studies used broader proteomic approaches to quantify inflammation. DNA methylation and histone modifications are less researched epigenetic mechanisms in perioperative inflammation. Future studies should recruit patients with homogeneous surgical insults. Studies should use standard measures of inflammation to enhance generalisability, whereas experimental approaches (including transcriptomics and proteomics) could advance mechanistic understanding in exploratory studies. Future research would benefit from consistent use of validated definitions of postoperative complications to enable comparison between studies.
中文摘要:术后过度炎症与手术后的多系统并发症相关,最终导致发病率、死亡率和医疗费用增加。表观遗传修饰在不改变DNA序列的情况下调节基因转录,并可增强强烈的炎症反应。已有转化研究探讨表观遗传机制如何影响围手术期炎症和并发症。本范围综述整合了这一不断扩展领域的研究,并为未来研究提供有依据的建议。本范围综述的方案依据最佳实践指南制定,并经过前瞻性注册和发表。检索使用Medline和Embase进行,纳入1946年至2025年间以英文发表的研究。两名评审员独立筛选标题和摘要,然后在数据提取前筛选研究的全文。纳入的研究探讨了术后并发症以及表观遗传机制和炎症。共评估了15,451项研究的标题和摘要筛选,最终26篇文章被纳入综述。纳入研究发表于2016年至2025年间。心脏外科最常被研究,其次是普通外科和结直肠外科。若干外科专业未被涵盖。大多数研究探讨microRNA机制,或研究少量microRNA(≤8个),或使用全转录组方法。DNA甲基化和组蛋白修饰被研究得较少。纳入研究对并发症的定义各不相同,且大多数研究仅关注少量并发症。炎症评估具有异质性,大多数研究使用C反应蛋白和白细胞介素-6或两者,而其他研究使用更广泛的蛋白质组学方法来量化炎症。DNA甲基化和组蛋白修饰是围手术期炎症中研究较少的表观遗传机制。未来研究应招募接受同质化手术创伤的患者。研究应使用标准化的炎症指标以提高可推广性,而实验方法(包括转录组学和蛋白质组学)可在探索性研究中推进机制理解。未来研究将受益于一致使用经过验证的术后并发症定义,以便研究间比较。